190 related articles for article (PubMed ID: 27226390)
1. First-in-class small molecule potentiators of cancer virotherapy.
Dornan MH; Krishnan R; Macklin AM; Selman M; El Sayes N; Son HH; Davis C; Chen A; Keillor K; Le PJ; Moi C; Ou P; Pardin C; Canez CR; Le Boeuf F; Bell JC; Smith JC; Diallo JS; Boddy CN
Sci Rep; 2016 May; 6():26786. PubMed ID: 27226390
[TBL] [Abstract][Full Text] [Related]
2. Triptolide-mediated inhibition of interferon signaling enhances vesicular stomatitis virus-based oncolysis.
Ben Yebdri F; Van Grevenynghe J; Tang VA; Goulet ML; Wu JH; Stojdl DF; Hiscott J; Lin R
Mol Ther; 2013 Nov; 21(11):2043-53. PubMed ID: 23985699
[TBL] [Abstract][Full Text] [Related]
3. Overcoming Barriers in Oncolytic Virotherapy with HDAC Inhibitors and Immune Checkpoint Blockade.
Marchini A; Scott EM; Rommelaere J
Viruses; 2016 Jan; 8(1):. PubMed ID: 26751469
[TBL] [Abstract][Full Text] [Related]
4. Interferon Beta and Interferon Alpha 2a Differentially Protect Head and Neck Cancer Cells from Vesicular Stomatitis Virus-Induced Oncolysis.
Westcott MM; Liu J; Rajani K; D'Agostino R; Lyles DS; Porosnicu M
J Virol; 2015 Aug; 89(15):7944-54. PubMed ID: 25995245
[TBL] [Abstract][Full Text] [Related]
5. Herpes simplex virus delivery to orthotopic rectal carcinoma results in an efficient and selective antitumor effect.
Kolodkin-Gal D; Edden Y; Hartshtark Z; Ilan L; Khalaileh A; Pikarsky AJ; Pikarsky E; Rabkin SD; Panet A; Zamir G
Gene Ther; 2009 Jul; 16(7):905-15. PubMed ID: 19440231
[TBL] [Abstract][Full Text] [Related]
6. PML has a predictive role in tumor cell permissiveness to interferon-sensitive oncolytic viruses.
Sobol PT; Hummel JL; Rodrigues RM; Mossman KL
Gene Ther; 2009 Sep; 16(9):1077-87. PubMed ID: 19474810
[TBL] [Abstract][Full Text] [Related]
7. Activation of Nrf2 Signaling Augments Vesicular Stomatitis Virus Oncolysis via Autophagy-Driven Suppression of Antiviral Immunity.
Olagnier D; Lababidi RR; Hadj SB; Sze A; Liu Y; Naidu SD; Ferrari M; Jiang Y; Chiang C; Beljanski V; Goulet ML; Knatko EV; Dinkova-Kostova AT; Hiscott J; Lin R
Mol Ther; 2017 Aug; 25(8):1900-1916. PubMed ID: 28527723
[TBL] [Abstract][Full Text] [Related]
8. Combination Therapy Using Ruxolitinib and Oncolytic HSV Renders Resistant MPNSTs Susceptible to Virotherapy.
Ghonime MG; Cassady KA
Cancer Immunol Res; 2018 Dec; 6(12):1499-1510. PubMed ID: 30352799
[TBL] [Abstract][Full Text] [Related]
9. In vitro screening of clinical drugs identifies sensitizers of oncolytic viral therapy in glioblastoma stem-like cells.
Berghauser Pont LM; Balvers RK; Kloezeman JJ; Nowicki MO; van den Bossche W; Kremer A; Wakimoto H; van den Hoogen BG; Leenstra S; Dirven CM; Chiocca EA; Lawler SE; Lamfers ML
Gene Ther; 2015 Dec; 22(12):947-59. PubMed ID: 26196249
[TBL] [Abstract][Full Text] [Related]
10. Expressing human interleukin-15 from oncolytic vesicular stomatitis virus improves survival in a murine metastatic colon adenocarcinoma model through the enhancement of anti-tumor immunity.
Stephenson KB; Barra NG; Davies E; Ashkar AA; Lichty BD
Cancer Gene Ther; 2012 Apr; 19(4):238-46. PubMed ID: 22158521
[TBL] [Abstract][Full Text] [Related]
11. Induction of apoptosis in pancreatic cancer cells by vesicular stomatitis virus.
Felt SA; Moerdyk-Schauwecker MJ; Grdzelishvili VZ
Virology; 2015 Jan; 474():163-73. PubMed ID: 25463614
[TBL] [Abstract][Full Text] [Related]
12. Oncotargeting by Vesicular Stomatitis Virus (VSV): Advances in Cancer Therapy.
Bishnoi S; Tiwari R; Gupta S; Byrareddy SN; Nayak D
Viruses; 2018 Feb; 10(2):. PubMed ID: 29473868
[TBL] [Abstract][Full Text] [Related]
13. Targeted inflammation during oncolytic virus therapy severely compromises tumor blood flow.
Breitbach CJ; Paterson JM; Lemay CG; Falls TJ; McGuire A; Parato KA; Stojdl DF; Daneshmand M; Speth K; Kirn D; McCart JA; Atkins H; Bell JC
Mol Ther; 2007 Sep; 15(9):1686-93. PubMed ID: 17579581
[TBL] [Abstract][Full Text] [Related]
14. Re-engineering vesicular stomatitis virus to abrogate neurotoxicity, circumvent humoral immunity, and enhance oncolytic potency.
Muik A; Stubbert LJ; Jahedi RZ; Geiβ Y; Kimpel J; Dold C; Tober R; Volk A; Klein S; Dietrich U; Yadollahi B; Falls T; Miletic H; Stojdl D; Bell JC; von Laer D
Cancer Res; 2014 Jul; 74(13):3567-78. PubMed ID: 24812275
[TBL] [Abstract][Full Text] [Related]
15. Recent advances in oncolytic virus-based cancer therapy.
Fu LQ; Wang SB; Cai MH; Wang XJ; Chen JY; Tong XM; Chen XY; Mou XZ
Virus Res; 2019 Sep; 270():197675. PubMed ID: 31351879
[TBL] [Abstract][Full Text] [Related]
16. Interleukin-12 expression enhances vesicular stomatitis virus oncolytic therapy in murine squamous cell carcinoma.
Shin EJ; Wanna GB; Choi B; Aguila D; Ebert O; Genden EM; Woo SL
Laryngoscope; 2007 Feb; 117(2):210-4. PubMed ID: 17204993
[TBL] [Abstract][Full Text] [Related]
17. In silico trials predict that combination strategies for enhancing vesicular stomatitis oncolytic virus are determined by tumor aggressivity.
Jenner AL; Cassidy T; Belaid K; Bourgeois-Daigneault MC; Craig M
J Immunother Cancer; 2021 Feb; 9(2):. PubMed ID: 33608375
[TBL] [Abstract][Full Text] [Related]
18. Directing systemic oncolytic viral delivery to tumors via carrier cells.
Nakashima H; Kaur B; Chiocca EA
Cytokine Growth Factor Rev; 2010; 21(2-3):119-26. PubMed ID: 20226717
[TBL] [Abstract][Full Text] [Related]
19. MicroRNA regulation of oncolytic herpes simplex virus-1 for selective killing of prostate cancer cells.
Lee CY; Rennie PS; Jia WW
Clin Cancer Res; 2009 Aug; 15(16):5126-35. PubMed ID: 19671871
[TBL] [Abstract][Full Text] [Related]
20. Multi-modal Potentiation of Oncolytic Virotherapy by Vanadium Compounds.
Selman M; Rousso C; Bergeron A; Son HH; Krishnan R; El-Sayes NA; Varette O; Chen A; Le Boeuf F; Tzelepis F; Bell JC; Crans DC; Diallo JS
Mol Ther; 2018 Jan; 26(1):56-69. PubMed ID: 29175158
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
